In CRC lines, KRAS G12C inhibition induces higher phospho-ERK rebound than in NSCLC cells and EGFR signaling is the dominant mechanism of CRC resistance to KRAS G12C inhibitors [14]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.